21 June 2016

Adaptimmune Announces Commercial Development and Supply Agreement with Thermo Fisher

Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that it has entered into a commercial development and supply agreement with Thermo Fisher Scientific. The new 10-year agreement augments Adaptimmune’s exclusive license and supply relationship with Thermo Fisher for the Dynabeads CD3/CD28 Cell Therapy System (CTS™)* for use in the manufacture of Adaptimmune’s SPEAR™ T-cell therapies. Source: Adaptimmune press release 21/6/2016

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).